XENON PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
XENON PHARMACEUTICALS INC. (XENE) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $22.62 per share as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-02-26
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 8.64 CAD/shares.
- 2019-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 7.17 CAD/shares.
- 2018-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 5.61 CAD/shares.
- 2017-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price 7.12 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2020-12-31 | 8.64 CAD/shares 10-K · filed 2021-03-01 |
| 2019-12-31 | 7.17 CAD/shares 10-K · filed 2021-03-01 |
| 2018-12-31 | 5.61 CAD/shares 10-K · filed 2020-03-09 |
| 2017-12-31 | 7.12 CAD/shares 10-K · filed 2019-03-06 |
| 2016-12-31 | 9.58 CAD/shares 10-K · filed 2018-03-07 |
| 2015-12-31 | 10.60 CAD/shares 10-K · filed 2017-03-08 |
| 2014-12-31 | 5.64 CAD/shares 10-K · filed 2016-03-08 |
| 2014-01-01 | 3.79 CAD/shares 10-K · filed 2015-03-12 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $22.62 10-K · filed 2026-02-26 |
| 2024-12-31 | $24.56 10-K · filed 2026-02-26 |
| 2023-12-31 | $20.53 10-K · filed 2025-02-27 |
| 2022-12-31 | $16.60 10-K · filed 2024-02-29 |
| 2021-12-31 | $10.56 10-K · filed 2023-03-01 |
| 2020-12-31 | $6.78 10-K · filed 2022-03-01 |
| 2019-12-31 | $5.51 10-K · filed 2021-03-01 |
| 2018-12-31 | $4.11 10-K · filed 2020-03-09 |
| 2017-12-31 | $5.66 10-K · filed 2019-03-06 |
| 2016-12-31 | $7.13 10-K · filed 2018-03-07 |
| 2015-12-31 | $8.54 10-K · filed 2017-03-08 |
| 2014-12-31 | $4.86 10-K · filed 2016-03-08 |
| 2014-01-01 | $3.54 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |